Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) CEO August J. Troendle bought 94,119 shares of the stock in a transaction on Wednesday, September 21st. The stock was purchased at an average price of $161.63 per share, for a total transaction of $15,212,453.97. Following the purchase, the chief executive officer now directly owns 6,425,593 shares of the company's stock, valued at $1,038,568,596.59. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.

Medpace Stock Performance

Shares of MEDP traded down $0.95 during trading hours on Thursday, hitting $154.83. 393,461 shares of the company were exchanged, compared to its average volume of 343,725. The firm's 50 day moving average is $161.31 and its 200-day moving average is $152.71. Medpace Holdings, Inc. has a 52 week low of $126.94 and a 52 week high of $231.00. The company has a market cap of $4.80 billion, a PE ratio of 26.88 and a beta of 1.47.

Medpace (NASDAQ:MEDP – Get Rating) last announced its earnings results on Monday, July 25th. The company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.12. Medpace had a return on equity of 30.56% and a net margin of 16.27%. The firm had revenue of $351.21 million during the quarter, compared to the consensus estimate of $344.01 million. During the same quarter in the prior year, the company earned $1.06 EPS. The firm's revenue for the quarter was up 26.2% compared to the same quarter last year. As a group, equities analysts forecast that Medpace Holdings, Inc. will post 6.16 earnings per share for the current fiscal year.

Institutional Trading of Medpace

Analyst Ratings Changes

Several research firms have recently issued reports on MEDP. StockNews.com downgraded Medpace from a "buy" rating to a "hold" rating in a research note on Thursday, September 8th. UBS Group began coverage on Medpace in a research note on Wednesday, September 7th. They set a "sell" rating and a $142.00 price target for the company.

About Medpace

(Get Rating)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Featured Stories

• Get a free copy of the StockNews.com research report on Medpace (MEDP)
• What Steelcase's Earnings Say About the Return to the Office?
• The Institutions Hold On To Darden Restaurants International
• These 3 Big Dividend Payers Also Boast Strong Price Growth
• Is The Golden Age Of Homebuilding Already Over?
• Natural Gas Prices Continue To Rally, These Stocks Should Benefit

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.